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Abstract Human breast cancer cell line Hs578T was stably
transfected with cDNA for cyclooxygenase-1 or -2. When the
cells overexpressing cyclooxygenase-1 or -2 were stimulated with
concanavalin A, the processing of matrix metalloproteinase-2
was observed with the aid of gelatin zymography. This processing
was not seen in mock-transfected and original cells which did not
express detectable cyclooxygenase activity. Furthermore, North-
ern blotting showed 8^13 fold induction of membrane-type 1
matrix metalloproteinase which processed matrix metallopro-
teinase-2 in the cells expressing cyclooxygenases. These findings
suggest that both isoforms of cyclooxygenase mediate the
processing of matrix metalloproteinase-2 through induction of
membrane-type 1 metalloproteinase in breast cancer cells.
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1. Introduction
Cyclooxygenase is a rate limiting enzyme for prostaglandin
(PG) synthesis from arachidonic acid. It incorporates two
molecules of oxygen into arachidonic acid and produces
PGG2 which is reduced by the same enzyme to PGH2. Two
isoforms of the enzyme are known; cyclooxygenase-1, which
is a constitutive enzyme expressed in many tissues, and cyclo-
oxygenase-2, which is an inducible enzyme synthesized at in-
£ammatory lesions by cytokines, growth factors and tumor
promoters [1,2]. A number of studies have demonstrated
that cyclooxygenases are expressed in tissues obtained from
various cancer lesions. The majority of these studies reported
an increased expression of cyclooxygenase-2 isoform in cancer
tissues [3^10], although the up-regulation of cyclooxygenase-1
was also documented [11,12]. While evidence for the mechan-
ical involvement of cyclooxygenases in the development of
colorectal cancer has been accumulating, the role of these
enzymes in other cancers has not been fully determined yet
[13^16].
The ¢nding that non-steroidal anti-in£ammatory drugs re-
duce the risk of breast cancer [17,18] suggests that cyclooxy-
genase is involved in the promotion of this type of cancer. In
fact, both cyclooxygenase-1 [11] and -2 [4,11] were reported to
be elevated in human breast cancer tissues. Furthermore, PG
production was reported to be greater in highly metastatic
breast cancer cells than in non-metastatic cells [19,20]. How-
ever, the involvement of the two cyclooxygenase isoforms in
the progress and metastasis of breast cancer is not yet fully
understood, although one report mentioned that overexpres-
sion of cyclooxygenase-2 in colon cancer CaCo2 cells in-
creased the metastatic potential [21]. The aim of this study
was to investigate whether the two cyclooxygenase isoforms
could a¡ect the expression of matrix metalloproteinases
(MMPs) related to cancer metastasis. Among MMPs, process-
ing by limited proteolysis of MMP-2 by membrane-type 1
MMP produces an active form which plays an important
role in metastasis [22]. We introduced the cDNA for each of
the two isoforms of cyclooxygenase into human breast cancer
Hs578T cells which originally did not show signi¢cant cyclo-
oxygenase activity and examined the activation of MMP-2
through the induction of membrane-type 1 MMP.
2. Materials and methods
2.1. Materials
Human breast cancer cells Hs578T were kindly provided by Dr. T.
Sasaki (Kanazawa University, Japan). Expression vector pEF-BOS
was a generous gift from Dr. S. Nagata (Osaka University, Japan).
[1-14C]Arachidonic acid (2.1 GBq/mmol), [K-32P]dCTP (111 TBq/
mmol), the Megaprime DNA labeling kit and Hybond-N+ nylon
membrane were purchased from Amersham (Buckinghamshire, UK),
QuikHyb hybridization solution from Stratagene (La Jolla, CA,
USA), restriction enzymes from Toyobo (Osaka, Japan), Isogen
from Nippongene (Tokyo, Japan), precoated silica gel plate for thin
layer chromatography from Merck (Darmstadt, Germany), concana-
valin A, indomethacin and geneticin from Sigma (St. Louis, MO,
USA), Iscove’s modi¢ed Dulbecco’s medium and lipofectamine from
Gibco BRL (Grand Island, NY, USA) and fetal bovine serum from
JRH Bioscience (Lenexa, KS, USA). CT1746 was provided by Cell-
tech (Slough, UK). All the other reagents were of analytical grade.
2.2. Cyclooxygenase assay
Hs578T cells (5U105/dish) were cultured in Iscove’s modi¢ed Dul-
becco’s medium supplemented with 5% fetal bovine serum, 100 units/
ml of penicillin G and 100 Wg/ml of streptomycin. The cells were
scraped from the dishes, suspended in 100 Wl of 50 mM Tris-HCl
(pH 7.4) and 1 mM EDTA, and sonicated on ice at 20 kHz three
times each for 5 s. The sonicated cells were then incubated at 24‡C for
10 min with 25 WM [1-14C]arachidonic acid (1.85 kBq/5 nmol/5 Wl
ethanol solution) in 200 Wl of 50 mM Tris-HCl bu¡er (pH 7.4) con-
taining 2 WM hematin and 5 mM tryptophan. The reaction was
quenched by the addition of ice-cold diethyl ether/methanol/1 M citric
acid (30:4:1, v/v) and the product was extracted into an ether layer
which was spotted onto a thin layer chromatography plate. The plate
was developed with an organic layer of ethyl acetate/water/2,2,4-tri-
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methylpentane/acetic acid (110:100:50:20, v/v) at room temperature.
The radioactive products on the plate were visualized and quanti¢ed
by a Fujix bioimaging analyzer BAS 1000 (Tokyo, Japan). Protein
concentration was determined by the method of Lowry et al. with
bovine serum albumin as the standard [23].
2.3. Construction of vectors and transfection
The expression vector pEF-BOS with a powerful elongation factor-
1K promoter [24,25] was digested with SapI, blunted with a Klenow
fragment, and ligated to a neomycin-resistant gene. The resultant
vector pBOSNeo was digested with XbaI and ligated to cDNAs for
human cyclooxygenase-1 [26] or cyclooxygenase-2 [27] with the XbaI
site attached at both ends. cDNAs for cyclooxygenase-1 and -2 were
fully sequenced with the dideoxynucleotide chain termination method
[28]. The constructs pBOSNeoCOX-1 and pBOSNeoCOX-2 as well as
the parental pBOSNeo vector (mock transfection) were transfected to
Hs578T with the aid of lipofectamine according to the manufacturer’s
instruction. After 3 days the cells were split at a ratio of 1:50 and
plated in the medium containing 1 mg/ml of geneticin. Approximately
100 colonies were taken from each transfection and their cyclooxyge-
nase expression was examined with the enzyme activity assay.
2.4. Gelatin zymography
Hs578T cells overexpressing cyclooxygenase-1 or cyclooxygenase-2
were plated in 35-mm dishes at a density of 5U104 cells/dish and
cultured overnight. The culture medium was changed to 500 Wl of
the medium without serum and compounds to be tested were added.
The cells were incubated for 18^24 h and 10 Wl of the medium was
subjected to 8% SDS-polyacrylamide gel electrophoresis containing
1 mg/ml of gelatin. The gel was washed twice in 50 mM Tris-HCl
(pH 7.5) containing 10 mM CaCl2, 2.5% Triton X-100, 0.02% NaN3
and 1 WM ZnCl2, and then incubated at 37‡C for 12 h in 50 mM Tris-
HCl (pH 7.5) containing 0.15 M NaCl, 10 mM CaCl2 and 0.02%
NaN3 followed by staining with Coomassie brilliant Blue R-250.
2.5. Northern blotting
Total RNA was isolated from the cells by using Isogen, and 20 Wg
of the denatured RNA was separated on 1% agarose gel. The RNA
was then transferred to Hybond-N+ nylon membrane and UV cross-
linked. The membrane was hybridized in QuikHyb hybridization so-
lution at 68‡C for 2 h with the membrane-type 1 MMP cDNA [22]
probe radiolabeled with the Megaprime DNA labeling kit. The mem-
brane was washed in 0.2USSC and 0.1% SDS at 65‡C for 30 min. The
radioactivity on the membrane was detected and quanti¢ed with the
Fujix bioimaging analyzer BAS 1000.
3. Results
3.1. Overexpression of cyclooxygenase-1 or -2 in the human
breast cancer cell line
When the sonicated human breast cancer Hs578T cells were
incubated with radiolabeled arachidonic acid, hardly any
products were observed on a thin layer chromatogram as
shown in Fig. 1. The cDNA for cyclooxygenase-1 or -2 was
inserted downstream of the powerful elongation factor-1K
promoter in pEF-BOS, which also contained a neomycin re-
sistant gene. The resultant vectors were then transfected to
Hs578T cells and geneticin resistant clones were selected. Sev-
eral clones from each of the transfections exhibited cyclooxy-
genase activity. Fig. 1 shows thin layer chromatography
analysis of the products in clones overexpressing cyclooxyge-
nase-1 or -2. The major product of both of these enzymes was
PGE2, although the minor production of 6-keto-PGF1K, a
degradation product of unstable prostacyclin, was also ob-
served. The clones with di¡erent speci¢c activities were se-
lected as shown in Table 1. The speci¢c activities were 0.06^
0.27 nmol/10 min/mg of protein in cyclooxygenase-expressing
cells, whereas mock-transfected cells exhibited hardly any en-
zyme activity.
3.2. MMP-2 activation in Hs578T cells overexpressing
cyclooxygenase-1 or -2
Hs578T cells were incubated with serum-free medium and
the harvested medium was subjected to gelatin zymography
(Fig. 2A). A band of 68 kDa was observed which corre-
sponded to the inactive form of MMP-2 in terms of its mo-
lecular weight. This was in agreement with previously re-
ported results showing that MMP-2 was expressed in
Hs578T [29,30]. The addition of concanavalin A to the cells
overexpressing either cyclooxygenase-1 or cyclooxygenase-2
resulted in the dramatic appearance of active forms of
MMP-2 (64 and 62 kDa) on gelatin zymography (Fig. 2A).
Concanavalin A is an inducer of membrane-type 1 MMP
which processes MMP-2 to convert it to its active forms
[22]. The clone COX-2^44, which showed the highest cyclo-
oxygenase activity (Table 1), produced by far the most densely
band of active forms, and the extent of processing appeared to
depend on the enzyme activity of the clones rather than on the
di¡erence in isoforms. These active forms of MMP-2 were not
observed in the original and mock-transfected cells stimulated
with concanavalin A. MMP-2 was not signi¢cantly processed
in cyclooxygenase-expressing cells without concanavalin A
treatment.
We also examined the e¡ects of cyclooxygenase inhibitors
on MMP-2 activation. The processing of MMP-2 in cyclooxy-
genase-overexpressing cells was not inhibited in the cells
treated with 50 WM indomethacin, a cyclooxygenase inhibitor
(Fig. 2B). Furthermore, the following inhibitors were tested
with the same results : aspirin at 200 WM, ketoprofen at 50 WM
and sulindac at 50 WM (data not shown). Preincubation for up
to 48 h of the cells with these inhibitors produced no change
in the results (data not shown). Only sulindac sul¢de at 50 WM
reduced the density of active forms (Fig. 2B). However, the
level of the inactive form was also reduced by this compound.
3.3. Induction of membrane-type 1 MMP in Hs578T cells
overexpressing cyclooxygenase-1 or -2
To investigate the mechanism of MMP-2 activation,
CT1746, a reversible and MMP species non-selective inhibitor
was employed. As shown in Fig. 2B, the active forms of
MMP-2 (64 kDa and 62 kDa) completely disappeared as a
Fig. 1. Thin layer chromatography analysis of arachidonic acid me-
tabolites in Hs578T cells overexpressing cyclooxygenase-1 or -2. The
cell extract (500 Wg protein) from the cells overexpressing cyclooxy-
genase-1 (COX-1-33 and -85) or cyclooxygenase-2 (COX-2-17 and
-44) was incubated with [1-14C]arachidonic acid under standard con-
ditions. The extract from original and mock-transfected cells was
also incubated. AA, arachidonic acid.
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result of the treatment of cyclooxygenase-expressing cells with
CT1746. This result agrees with the previous ¢nding that
membrane-type 1 MMP is necessary for the processing of
MMP-2 [22]. We further examined by means of Northern
blot analysis whether membrane-type 1 MMP mRNA would
be increased in the cyclooxygenase-expressing Hs578T cells.
As shown in Fig. 3, the expression level of membrane-type 1
MMP was very low in the mock-transfected cells, and the
treatment of the cells with concanavalin A showed a four-
fold increase of membrane-type 1 MMP mRNA as compared
with the non-treated cells. However, when cyclooxygenase-ex-
pressing cells were incubated with concanavalin A, a striking
induction of membrane-type 1 MMP mRNA was observed
(8^13-fold, Fig. 3B). Without concanavalin A treatment,
membrane-type 1 MMP mRNA was increased two- to
three-fold in the cyclooxygenase-expressing cells compared
to the mock-transfected cells.
4. Discussion
We have demonstrated that overexpression of either cyclo-
oxygenase-1 or cyclooxygenase-2 in human breast cancer
Hs578T cells brought about the dramatic activation of
MMP-2 as a result of treatment with concanavalin A (Fig.
2A). The level of the activation appeared to depend on the
enzyme activity of cyclooxygenases rather than on the di¡er-
ence in isoforms. The activation of MMP-2 could be ex-
plained by the strikingly increased expression level of mem-
brane-type 1 MMP mRNA in the cyclooxygenase-expressing
cells (Fig. 3). Concanavalin A by itself has been shown to
elevate membrane-type 1 MMP mRNA both by transcription-
al activation and mRNA stabilization but the elevation was
not dramatic [31^33]. Under our experimental conditions too,
only a slight induction produced by concanavalin A was ob-
served in the mock-transfected cells (Fig. 3). Only a few stud-
ies have demonstrated that membrane-type 1 MMP expres-
sion and MMP-2 activation are induced from almost
undetectable to high levels [34,35]. It is known that the extent
of MMP-2 activation is not necessarily proportional to the
expression level of membrane-type 1 MMP, which implies
that there is a threshold of membrane-type 1 MMP level for
MMP-2 activation [32]. At least two molecules of membrane-
type 1 MMP are thought to be required for MMP-2 process-
ing, one functioning as substrate presentation complex and
the other as a processing enzyme, and these two components
should be near each other for e⁄cient MMP-2 processing to
take place on the cell surface [36]. Under our experimental
conditions, this threshold level of membrane-type 1 MMP
Table 1
Cyclooxygenase activities in Hs578T cells overexpressing cyclooxyge-
nase-1 or -2
Clone Cyclooxygenase activity
(nmol/10 min/mg of protein)
Control Indomethacin Sulindac sul¢de
Original 6 0.02 ND ND
Mock-transfected 6 0.02 ND ND
COX-1-33 0.18 6 0.02 0.03
COX-1-85 0.17 6 0.02 0.06
COX-2-17 0.06 6 0.02 0.05
COX-2-44 0.27 6 0.02 0.22
The cells overexpressing cyclooxygenase-1 (COX-1-33 and -85) or
cyclooxygenase-2 (COX-2-17 and -44) as well as original and mock-
transfected cells were sonicated and enzyme activities were deter-
mined as described in Section 2. Indomethacin or sulindac sul¢de
was added at a concentration of 5 WM. ND, not determined.
Fig. 2. MMP-2 activation in cyclooxygenase-overexpressing Hs578T
cells treated with concanavalin A. A: Cells overexpressing cyclooxy-
genase-1 (COX-1-33 and -85) or cyclooxygenase-2 (COX-2-17 and
-44) as well as original and mock-transfected cells were incubated in
the absence (Control) or presence of 20 Wg/ml of concanavalin A
(Con A). The harvested medium was analyzed by means of gelatin
zymography as described in Section 2. B: E¡ect of various inhibi-
tors on the processing of MMP-2. Indomethacin and sulindac sul-
¢de at 50 WM and CT1746, a reversible and MMP species non-se-
lective inhibitor, at 5 WM were included in addition to concanavalin
A.
Fig. 3. Membrane-type 1 MMP induction in cyclooxygenase-overex-
pressing Hs578T cells stimulated by concanavalin A. A: Northern
blot analysis of membrane-type 1 MMP. Cells overexpressing cyclo-
oxygenase-1 (COX-1-85) or cyclooxygenase-2 (COX-2-44) as well as
mock-transfected cells were incubated for 6 h in the absence (Con-
trol) or presence of 20 Wg/ml of concanavalin A (Con A). Total
RNA was subjected to Northern blot analysis using radiolabeled
membrane-type 1 MMP as a probe. Ethidium bromide staining of
18S ribosomal RNA is also shown. B: Radioactivity was quanti¢ed
and normalized with the intensity of 18S ribosomal RNA, which
was determined by NIH image software. Ratios over MMP mRNA
of mock cells without concanavalin A are shown.
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seemed to be at least ¢ve times higher than the basal level in
the cyclooxygenase-expressing Hs578T cells (Fig. 3B).
As far as we were able to determine, no signi¢cant inhibi-
tion of MMP-2 activation by cyclooxygenase inhibitors could
be observed (Fig. 2B). Even prolonged incubation of the cells
up to 48 h with these inhibitors before addition of concana-
valin A yielded the same results. Of the various inhibitors
tested, only sulindac sul¢de caused a slight decrease in the
amount of activated forms of MMP-2 (Fig. 2B) but this com-
pound also suppressed the level of the inactive form. This
might be explained by the fact that more than 30% of cells
had died after 18 h incubation with sulindac sul¢de as as-
sessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-tetrazolium bro-
mide (MTT) assay (data not shown). Furthermore, sulindac
sul¢de only partially inhibited cyclooxygenase activity, where-
as indomethacin completely inhibited the enzyme activity (Ta-
ble 1). It was described that MMP-2 activation was inhibited
by 50 WM sulindac sul¢de in human colon cancer CaCo2 cells
overexpressing cyclooxygenase-2 [21]. In any case, however,
addition of PGE2, PGF2K or PGD2 could not activate
MMP-2 by itself ([21] and F. Kawahara et al., unpublished
observations). It has also been reported that the stimulated
growth of immortalized ECV endothelial cells which were
tumorigenically transformed by cyclooxygenase-1 overexpres-
sion was not inhibited by indomethacin [37]. These ¢ndings
suggest that cyclooxygenases exert their pathophysiological
functions not only through PG production but also by means
of unknown mechanisms in the growth and metastasis of can-
cer cells [37]. In this connection, it is of interest that a protein
speci¢cally interacting with cyclooxygenase-1 and cyclooxyge-
nase-2 has been identi¢ed [38].
In summary, we were able to demonstrate that both cyclo-
oxygenase-1 and -2 play a role in the activation of MMP-2 via
membrane-type 1 MMP induction in a human breast cancer
cell line. It should be mentioned that not only cyclooxygenase-
2 but also cyclooxygenase-1 is up-regulated in breast cancer
tissues [4,11]. Our ¢ndings, combined with those by other
investigators, suggest that both isoforms of cyclooxygenase
play a role in the pathophysiology of breast cancer.
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